HK1215731A1 - 借助抗利尿激素原对呼吸道和肺部的感染及慢性病的诊断和风险性分级 - Google Patents

借助抗利尿激素原对呼吸道和肺部的感染及慢性病的诊断和风险性分级 Download PDF

Info

Publication number
HK1215731A1
HK1215731A1 HK16103639.3A HK16103639A HK1215731A1 HK 1215731 A1 HK1215731 A1 HK 1215731A1 HK 16103639 A HK16103639 A HK 16103639A HK 1215731 A1 HK1215731 A1 HK 1215731A1
Authority
HK
Hong Kong
Prior art keywords
use according
infections
patients
diagnosis
fragments
Prior art date
Application number
HK16103639.3A
Other languages
English (en)
Chinese (zh)
Inventor
．博格曼
A．博格曼
．莫根塔勒
N．莫根塔勒
．帕帕索提裡奧
J．帕帕索提里奥
．斯塔克
J.斯塔克
．穆勒
B.穆勒
Original Assignee
布拉姆斯有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 布拉姆斯有限公司 filed Critical 布拉姆斯有限公司
Publication of HK1215731A1 publication Critical patent/HK1215731A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16103639.3A 2006-11-12 2016-03-30 借助抗利尿激素原对呼吸道和肺部的感染及慢性病的诊断和风险性分级 HK1215731A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006053442.5 2006-11-12
DE102006053442A DE102006053442A1 (de) 2006-11-12 2006-11-12 Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II

Publications (1)

Publication Number Publication Date
HK1215731A1 true HK1215731A1 (zh) 2016-09-09

Family

ID=39277664

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103639.3A HK1215731A1 (zh) 2006-11-12 2016-03-30 借助抗利尿激素原对呼吸道和肺部的感染及慢性病的诊断和风险性分级

Country Status (10)

Country Link
US (3) US8158368B2 (enExample)
EP (2) EP2089718B1 (enExample)
JP (3) JP5340160B2 (enExample)
CN (2) CN105092858A (enExample)
AT (1) ATE522814T1 (enExample)
DE (1) DE102006053442A1 (enExample)
DK (1) DK2378290T3 (enExample)
ES (2) ES2370071T3 (enExample)
HK (1) HK1215731A1 (enExample)
WO (1) WO2008058517A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140046407A1 (en) * 2001-08-31 2014-02-13 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
EP1628136A1 (en) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Method of diagnosis of disease using copeptin
DE102006046996A1 (de) * 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz
JP5320294B2 (ja) * 2006-10-26 2013-10-23 ベー．エル．アー．ハー．エム．エス ゲーエムベーハー プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化
DE102007009751A1 (de) 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens
US20120329666A1 (en) * 2009-10-05 2012-12-27 Duke University Peripheral Blood Biomarkers for Idiopathic Interstitial Pneumonia and Methods of Use
CA2854563A1 (en) 2011-11-11 2013-05-16 Woomera Therapeutics Provasopressin antagonists and uses thereof
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
WO2023191145A1 (ko) 2022-03-31 2023-10-05 (주)네오닉스 배터리팩

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227454C1 (de) 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
DE19600875C1 (de) * 1996-01-12 1997-06-26 Brahms Diagnostica Gmbh Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse
DE19847690A1 (de) 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
ATE356874T1 (de) 1999-12-22 2007-04-15 Dade Behring Marburg Gmbh Lösungen von humanem procalcitonin
DE10027954A1 (de) 1999-12-22 2001-06-28 Dade Behring Marburg Gmbh Humanes Procalcitonin, dessen Herstellung und Verwendung
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
DE60335387D1 (de) * 2002-07-16 2011-01-27 Woomera Therapeutics Inc Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen
WO2004059293A2 (en) * 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
GB0401730D0 (en) * 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
EP1628136A1 (en) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Method of diagnosis of disease using copeptin
DE102004047968A1 (de) * 2004-10-01 2006-04-06 B.R.A.H.M.S Ag Bestimmung von Gastrokine 1 (GKN1) als Biomarker für Entzündungen und Infektionen
GB0508863D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Peptide
DE102007021443A1 (de) * 2007-05-08 2008-11-13 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels NT-proET-1
JP4983525B2 (ja) * 2007-10-11 2012-07-25 住友電装株式会社 ワイヤハーネスのプロテクタ取付構造
CN102428368B (zh) * 2009-05-05 2015-04-22 B.R.A.H.M.S有限公司 患有内皮功能/功能障碍相关疾病的患者的基于血管活性激素的分层

Also Published As

Publication number Publication date
US20170059583A1 (en) 2017-03-02
US20100041064A1 (en) 2010-02-18
ES2370071T3 (es) 2011-12-12
WO2008058517A3 (de) 2008-10-23
US10718783B2 (en) 2020-07-21
JP6170101B2 (ja) 2017-07-26
WO2008058517A2 (de) 2008-05-22
JP2010509576A (ja) 2010-03-25
ES2634137T3 (es) 2017-09-26
DK2378290T3 (en) 2017-07-31
CN101563613A (zh) 2009-10-21
US8158368B2 (en) 2012-04-17
EP2089718A2 (de) 2009-08-19
JP2016026286A (ja) 2016-02-12
JP2013083664A (ja) 2013-05-09
EP2378290A1 (de) 2011-10-19
EP2378290B1 (de) 2017-05-03
JP5340160B2 (ja) 2013-11-13
US20120270245A1 (en) 2012-10-25
ATE522814T1 (de) 2011-09-15
EP2089718B1 (de) 2011-08-31
DE102006053442A1 (de) 2008-05-15
CN105092858A (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
HK1215731A1 (zh) 借助抗利尿激素原对呼吸道和肺部的感染及慢性病的诊断和风险性分级
CN110431425B (zh) proADM作为指示不良事件的标志物
JP5828849B2 (ja) 無症候性患者における全身性炎症反応症候群およびセプシスの早期診断および予測に基づくｉｌ−６の検出
CN109564225B (zh) 作为指示不良事件的标志物的组蛋白和/或proADM
JP2010506146A (ja) 心不全を伴う気道および肺の感染または炎症性疾患の診断
WO2009006347A2 (en) Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
RU2764766C2 (ru) Гистоны и/или proadm в качестве маркеров, свидетельствующих об органной дисфункции
US20100261284A1 (en) Using gdf 15 to assess patients presenting to emergency units
CN118638739B (zh) Gsdmd在胸痛相关疾病诊断及疗效评估上的用途
JP2022534034A (ja) ＨＦｐＥＦのためのＩＧＦＢＰ７の比
HK1135183A (en) Diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs by means of provasopressin, particularly copeptin or neurophysin ii
RU2775090C2 (ru) Проадреномедуллин в качестве маркера, указывающего на неблагоприятное событие
HK40017069B (en) Proadm as marker indicating an adverse event
HK40017069A (en) Proadm as marker indicating an adverse event
HK40029756B (zh) 使用降钙素原和中区肾上腺髓质素原的风险评估和患者管理的工作流程
HK1137807B (en) Diagnosis of infections or inflammatory diseases of the airways and lungs associated with heart failure
HK40006968A (en) Histones and/or proadm as markers indicating an adverse event
HK40006968B (en) Histones and/or proadm as markers indicating an adverse event
HK1177963B (en) Il-6 detection based early diagnosis and prediction of systemic inflammatory response syndrome and sepsis in asymptomatic patients
EP2650684A1 (en) Pro SP-B and NT-proBNP based diagnosis in patients with pneumonia